Back to portfolio

Adaptimmune Limited plc (ADAP)

Transforming cancer immunotherapy with affinity enhanced T-cell receptors

Adaptimmune spun out of Oxford University in 2008 and maintains a research base in Oxford, UK and a clinical base in Philadelphia, PA, USA. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. In 2020, Adaptimmune has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications and a strong pipeline. The company went public in May of 2015.